Latest news with #Sublocade
Yahoo
4 days ago
- Business
- Yahoo
Drugmaker Indivior to abandon London listing amid exodus of companies
The drugmaker Indivior has become the latest company to abandon its listing in London, heaping further pressure on the London Stock Exchange (LSE) to reinvigorate itself. The Virginia-based company, which makes the opioid addiction treatments Sublocade and Suboxone, switched its main stock listing to the US last year, but now plans to cancel the secondary listing it had retained in London. Indivior said on Monday that in making the decision it had considered the liquidity and trading volumes of its shares on the US's Nasdaq exchange compared with the LSE; the location of its shareholders; and the cost and administrative requirements related to the London listing. More than 80% of Indivior's net revenues come from the US, which has been in the grip of an opioid crisis for decades, after a rise in the use of opioid painkillers led to increasing addiction rates and a sharp rise in fatal overdoses. David Wheadon, the Indivior chair, said: 'A single primary listing on Nasdaq best reflects the profile of Indivior's business. We appreciate the support received from shareholders for this initiative and look forward to capitalising on the expected benefits of this move, including reductions in cost and complexity.' The London-listed share price fell by 2% to 925.7p on Monday, giving Indivior a market value of nearly £1.2bn. The LSE has been hit by an exodus of companies, such as the Anglo-German travel company Tui, which opted for a sole listing in Frankfurt last year. 'The London Stock Exchange will be upset it is losing another big name,' said Russ Mould, the investment director at AJ Bell. 'It means the pressure is on to attract new names to the market and keep existing ones.' The blow was softened as the LSE welcomed Anglo American's $11bn (£8bn) platinum spin-off Valterra, which became independent from the mining company. Valterra is listed in South Africa and will now have a London listing as well. Anglo retains a 19.9% stake for now but has promised to sell it down over time. Mould said he had expected Indivior to exit London entirely, as its business is focused on the US, where most of its shareholders are based. The company had been listed in London because it was spun off in 2014 from the UK consumer goods group Reckitt Benckiser, itself listed in London. Indivior appointed the pharma veteran Joseph Ciaffoni as chief executive in February, replacing Mark Crossley after warning of a sharp drop in revenues this year. Last year it posted 9% sales growth to almost $1.2bn. This was driven by Sublocade, a prescription medicine that is injected once a month by health professionals to treat addiction to opioid drugs in adults, alongside mental health support. Suboxone is a similar drug but is given as tablets or as a film that dissolves when placed under the tongue. Sublocade's 2025 sales are expected to be flat compared with last year, while Suboxone film faces a 50% slump in sales because of competition from generic drugs, and Indivior will discontinue Perseris, its once-monthly schizophrenia drug. Indivior also said in February it faced 'numerous lawsuits', including an allegation that Suboxone film was 'defectively designed and caused dental injury'. There have also been cases brought by shareholders in the UK and US. Indivior faces a lawsuit from Wirral council, which administers the Merseyside Pension Fund, in London's high court over alleged false marketing of Suboxone. The case was thrown out in 2023; Wirral council appealed, and Indivior said in February it intended to 'vigorously defend' itself. In 2019, the US justice department charged Indivior with fraudulently claiming Suboxone film was better and safer than similar drugs. Its former parent, Reckitt, agreed to pay a $1.4bn fine to settle the case in July 2019, without any admission of wrongdoing, while Indivior said in 2020 that it had 'pleaded guilty to one count of making a false statement relating to healthcare matters in 2012' and that it would make payments to federal and state authorities totalling $600m over seven years. Shaun Thaxter, the former Indivior chief executive, was sentenced to six months in federal prison in 2020 after pleading guilty to his role in a scheme to secure Medicaid coverage for Suboxone film by misleading officials about its dangers to children.
The Guardian
4 days ago
- Business
- The Guardian
Drugmaker Invidior to abandon London listing amid exodus of companies
The drugmaker Indivior has become the latest company to abandon its listing in London, heaping further pressure on the London Stock Exchange (LSE) to reinvigorate itself. The Virginia-based company, which makes the opioid addiction treatments Sublocade and Suboxone, switched its main stock listing to the US last year, but now plans to cancel the secondary listing it had retained in London. Indivior said on Monday that in making the decision it had considered the liquidity and trading volumes of its shares on the US's Nasdaq exchange compared with the LSE; the location of its shareholders; and the cost and administrative requirements related to the London listing. More than 80% of Indivior's net revenues come from the US, which has been in the grip of an opioid crisis for decades, after a rise in the use of opioid painkillers led to rising addiction rates and a sharp rise in fatal overdoses. David Wheadon, the Indivior chair, said: 'A single primary listing on Nasdaq best reflects the profile of Indivior's business. We appreciate the support received from shareholders for this initiative and look forward to capitalising on the expected benefits of this move, including reductions in cost and complexity.' The London-listed share price fell by 2% to 925.7p on Monday, giving Indivior a market value of £1.2bn. The LSE has been hit by an exodus of companies, such as the Anglo-German travel company Tui, which opted for a sole listing in Frankfurt last year. 'The London Stock Exchange will be upset it is losing another big name,' said Russ Mould, the investment director at AJ Bell. 'It means the pressure is on to attract new names to the market and keep existing ones.' The blow was softened as the LSE welcomed Anglo American's $11bn (£8bn) platinum spin-off Valterra, which became independent from the mining company. Valterra is listed in South Africa and will now have a London listing as well. Anglo retains a 19.9% stake for now but has promised to sell it down over time. Mould said he had expected Indivior to exit London entirely, as its business is focused on the US, where most of its shareholders are based. The company had been listed in London because it was spun off in 2014 from the UK consumer goods group Reckitt Benckiser, itself listed in London. Indivior appointed the pharma veteran Joseph Ciaffoni as chief executive in February, replacing Mark Crossley after warning of a sharp drop in revenues this year. Last year it posted 9% sales growth to almost $1.2bn. This was driven by Sublocade, a prescription medicine that is injected once a month by health professionals to treat addiction to opioid drugs in adults, alongside mental health support. Suboxone is a similar drug but is given as tablets or as a film that dissolves when placed under the tongue. Sublocade's 2025 sales are expected to be flat compared with last year, while Suboxone film faces a 50% slump in sales because of competition from generic drugs, and Indivior will discontinue Perseris, its once-monthly schizophrenia drug. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion Indivior also said in February it faced 'numerous lawsuits', including an allegation that Suboxone film was 'defectively designed and caused dental injury'. There have also been cases brought by shareholders in the UK and US. Indivior faces a lawsuit from Wirral council, which administers the Merseyside Pension Fund, in London's high court over alleged false marketing of Suboxone. The case was thrown out in 2023; Wirral council appealed, and Indivior said in February it intended to 'vigorously defend' itself. In 2019, the US justice department charged Indivior with fraudulently claiming Suboxone film was better and safer than similar drugs. Its former parent, Reckitt, agreed to pay a $1.4bn fine to settle the case in July 2019, without any admission of wrongdoing, while Indivior said in 2020 that it had 'pleaded guilty to one count of making a false statement relating to healthcare matters in 2012' and that it would make payments to federal and state authorities totalling $600m over seven years. Shaun Thaxter, the former Indivior chief executive, was sentenced to six months in federal prison in 2020 after pleading guilty to his role in a scheme to secure Medicaid coverage for Suboxone film by misleading officials about its dangers to children.
Yahoo
4 days ago
- Business
- Yahoo
Drug maker Indivior joins the flight from London share listings
Drug maker Indivior has become the latest major UK listed company to scrap its London share trading. The pharmaceuticals company, which has its UK headquarters in Slough, said it planned to cancel its secondary listing in London. Indivior only moved its primary listing to Nasdaq last June and now wants to sever all share trading links with the City. The move comes just a year after Invidior's board said it planned to keep the London listing "for as long as it is considered to be in the best interests of Indivior and its shareholders as a whole." Reasons given for scrapping the London listing following a review include the fact that 80% of the company's revenue is generated in America; trading on Nasdaq accounts for approximately 75% of total volumes across both exchanges; more than 70% of the share are now held by investors located in the U.S; and the elimination of 'the cost and complexity of maintaining a secondary listing.' Another major factor is that the company's biggest selling drug Sublocade, a treatment for helping opioid addicts reduce their dependence, has its biggest market in the US. Last year Sublocade accounted for $756 million of the company's total $1.2 billion sales. Indivior was spun out of its former parent company, the consumer products giant Reckitt Benckizer in 2014 as a free standing London listed company. The Virginia based company's chair David Wheadon, said:"We are pleased to announce this key milestone for Indivior following our evaluation period. A single primary listing on Nasdaq best reflects the profile of Indivior's business. 'We appreciate the support received from shareholders for this initiative and look forward to capitalizing on the expected benefits of this move, including reductions in cost and complexity." London has suffered a major outflow of listed companies over recent years in a blow to the prestige of the City. A total of 88 firms delisted or transferred their primary listing from the London Stock Exchange last year, the highest number since the financial crisis of 2008, according to auditor EY. Only 18 companies came on to the London market last year as the vital flow of small and growing businesses raising capital by listing their shares on the London stock market dried up. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time Business News
29-05-2025
- Health
- Time Business News
The Dangers of Meth Addiction and How to Find Help
Methamphetamine addiction is a merciless affliction. What begins as a brief encounter with heightened energy and elation can swiftly metastasize into a debilitating dependency. This synthetic stimulant does not simply alter mood—it hijacks cognition, devastates the body, and dismantles lives. Its effects are fast, but its consequences are enduring. Early recognition and decisive action can make the difference between irreversible decline and meaningful recovery. Choosing the Right Path for Opioid Recovery When comparing treatment options for opioid use disorder, it's important to understand the differences between Sublocade and Suboxone. Sublocade is a once-monthly injectable medication, while Suboxone is typically taken daily in a sublingual film or tablet form. Both contain buprenorphine, a medication that helps reduce cravings and withdrawal symptoms. However, Sublocade may offer more consistent blood levels and improved adherence for those who struggle with daily dosing. On the other hand, Suboxone provides more flexibility and can be adjusted as needed. Choosing between Sublocade vs Suboxone often depends on lifestyle, medical history, and treatment goals. Understanding Methamphetamine and Its Immediate Effects Methamphetamine, commonly known as meth, is a powerful central nervous system stimulant. It is often smoked, snorted, injected, or swallowed. Regardless of the method of use, its onset is rapid. Users experience a surge of euphoria—sharp, crystalline, almost superhuman. There's heightened alertness, a false sense of confidence, and a feeling of invincibility. But this high is treacherous. It taxes the body's resources, causing users to go without food or sleep for days. Beneath the surface euphoria, the brain is quietly beginning to unravel. The Neurological Damage Caused by Meth Meth unleashes an overwhelming flood of dopamine—a neurotransmitter responsible for pleasure, motivation, and reward. In normal quantities, dopamine regulates emotional balance and goal-directed behavior. But methamphetamine causes an unnaturally large surge, burning out dopamine receptors in the process. With chronic use, the brain becomes chemically depleted. Natural pleasure fades. Motivation wanes. Many users develop meth-induced psychosis, manifesting as hallucinations, delusions, and extreme paranoia. The brain begins to misfire, processing fear as fact and illusion as reality. Physical and Physiological Consequences The physical toll of meth is both grotesque and grievous. One of the most visible signs is 'meth mouth'—a combination of dry mouth, tooth decay, and gum disease that often leads to the rapid deterioration of dental health. Skin-picking behaviors, fueled by tactile hallucinations, cause open sores and infections. Nutritional neglect leads to emaciation and weakened immunity. Meth places intense pressure on the cardiovascular system. Irregular heartbeats, hypertension, and an increased risk of stroke or heart attack are common. Respiratory issues can develop, especially in those who smoke the drug. Over time, the immune system erodes, leaving users vulnerable to infection and disease. Behavioral and Social Deterioration Meth addiction often fuels erratic and dangerous behavior. Users may become aggressive, impulsive, or delusional. Risky sexual encounters, criminal activity, and violent outbursts become frequent. The substance transforms once-rational individuals into unpredictable shadows of themselves. Social structures collapse. Relationships erode under the weight of mistrust and betrayal. Users become isolated—both by choice and by circumstance. Meth doesn't just damage the individual; it radiates devastation into families, workplaces, and entire communities. Withdrawal and the Trap of Relapse Meth withdrawal is more psychological than physical, but no less brutal. Depression, anhedonia (the inability to feel pleasure), anxiety, and fatigue overwhelm the user. Sleep disturbances and intense cravings persist for weeks or months. This post-acute withdrawal syndrome leaves individuals vulnerable to relapse. Without proper intervention, the brain's distorted wiring drives them back to the drug—not out of desire, but desperation to feel 'normal' again. The cycle tightens. Without structured support, escape becomes increasingly elusive. Finding Effective Help and Treatment Options Recovery is possible, but it demands a multifaceted approach. The first step is medical detox, where withdrawal symptoms are managed under professional supervision. This is followed by a structured rehabilitation program that addresses both the physical and psychological dimensions of addiction. Cognitive-behavioral therapy (CBT), contingency management, and motivational enhancement therapy are commonly used evidence-based approaches. Group counseling and peer support groups such as Crystal Meth Anonymous provide critical community and accountability. Long-term recovery hinges on continued support, lifestyle change, and relapse prevention planning. Naloxone, a life-saving medication used to reverse opioid overdoses, can be given through several administration routes depending on the situation and available resources. The most common administration routes for naloxone include intranasal spray, intramuscular injection, and intravenous injection. Intranasal spray is popular due to its ease of use and non-invasive nature, making it accessible for bystanders. Intramuscular injection, often delivered via an auto-injector or syringe, is another effective method, especially in emergency medical settings. Intravenous administration is usually reserved for hospital use, providing rapid onset of action during severe overdose cases. Conclusion Meth addiction is a scourge with far-reaching consequences—but it is not an inescapable fate. With timely intervention, comprehensive treatment, and unwavering support, healing can begin. The brain can repair. The body can recover. Life, once hijacked, can be reclaimed. The journey is arduous, but within reach—one step away from darkness, toward renewal. TIME BUSINESS NEWS
Time Business News
07-05-2025
- Health
- Time Business News
The Benefits of Faith-Based Addiction Recovery Programs
Introduction In the quest for sobriety, many find that conventional therapy alone doesn't quite satiate the spiritual hunger left in addiction's wake. This is where faith-based addiction recovery programs enter as a compelling paradigm—where healing extends beyond chemical dependency to touch the metaphysical core of a person. These programs do more than treat symptoms; they reintroduce the individual to a life imbued with purpose, community, and moral clarity. Sublocade and Suboxone are both medications used to treat opioid use disorder, but they differ in form, administration, and duration of action. While is sublocade the same as suboxone may seem like a straightforward question, the answer lies in their distinct delivery methods. Suboxone is a sublingual film or tablet taken daily, combining buprenorphine and naloxone to prevent withdrawal and reduce cravings. Sublocade, on the other hand, is a monthly injection that delivers a steady dose of buprenorphine without naloxone. These differences can influence patient adherence and treatment effectiveness, making personalized medical guidance essential when choosing between the two. Holistic Healing Through Spiritual Guidance Faith-based recovery programs operate on a foundational belief: that addiction is not merely a biological ailment but a spiritual affliction. This perspective allows these programs to deliver holistic healing—tending not just to the mind and body, but also to the soul. Prayer, meditation, and scripture readings are not adjunctive; they are central, forming a stabilizing latticework around which recovery is structured. Participants often report a rekindled sense of inner harmony, where spiritual rituals become instruments of emotional calibration. The act of surrendering control to a higher power, a tenet common to many faith traditions, brings a profound psychological relief that secular models sometimes fail to replicate. Community and Fellowship in Faith-Based Recovery Addiction thrives in isolation. Faith-based programs counteract this with a powerful antidote: fellowship. Shared belief systems forge strong interpersonal bonds that are not only emotional but spiritual. Within these circles, accountability flourishes—not from external pressure, but from a collective desire to uphold shared values. This sacred kinship, whether in the form of prayer groups, Bible studies, or spiritual mentorship, offers a safe space for vulnerability. In the crucible of mutual trust and faith, healing accelerates. People no longer feel alone in their struggle; they are woven into a tapestry of hope and redemption. Moral Framework and Purpose-Driven Recovery At the heart of faith-based recovery is the reconstitution of a moral compass. Addiction often dismantles one's identity, leading to a loss of direction and self-worth. Faith-based programs help rebuild these foundations by anchoring recovery in timeless ethical principles. Whether it's the Christian ethos of grace and forgiveness, the Islamic value of inner jihad (struggle), or the Buddhist principle of mindfulness and compassion, faith traditions offer a moral scaffold on which to reconstruct a life of integrity. This values-based approach enables individuals to see sobriety not as a limitation, but as a gateway to higher purpose. Reduced Relapse Rates in Spiritually-Inclined Programs Data suggests that individuals involved in spiritually oriented recovery programs often exhibit lower relapse rates. While not a panacea, faith functions as a protective buffer—its practices fostering mental fortitude, emotional resilience, and moral vigilance. Regular spiritual discipline—daily devotionals, community worship, scriptural engagement—creates structured rhythms that reinforce sobriety. In these routines, participants find solace, strength, and a renewed sense of identity, making them less susceptible to the temptations of relapse. Integration of Prayer, Scripture, and Worship The spiritual tools employed in faith-based programs are not ornamental—they are deeply therapeutic. Prayer becomes a dialogue with the divine, calming anxiety and instilling hope. Scripture offers timeless wisdom and perspective, guiding individuals through moments of despair with sacred encouragement. Worship, in its many forms—singing, meditation, ritual—unlocks catharsis and renewal. These practices help regulate emotions, dissipate cravings, and generate a sense of spiritual alignment. For many, these rituals become lifelong habits that sustain sobriety well beyond formal treatment. Accessibility and Support Beyond Formal Treatment One of the most enduring benefits of faith-based recovery programs is their integration with local religious communities. These communities extend support beyond the clinical timeline, offering ongoing mentorship, spiritual counseling, and social reinforcement. Faith institutions often open their doors to those in recovery, providing not just spiritual nourishment but tangible support: job training, housing assistance, family counseling. The church, mosque, synagogue, or temple becomes more than a place of worship—it becomes a sanctuary for continued growth and healing. Naloxone is a critical medication used to reverse opioid overdoses, often restoring breathing within minutes. Its effectiveness depends largely on how quickly it can be administered in emergency situations. For those wondering what are common administration routes for naloxone , the primary methods include intranasal (nasal spray), intramuscular (injection into the muscle), subcutaneous (under the skin), and intravenous (directly into a vein). The nasal spray is especially popular due to its ease of use by non-medical individuals. These various delivery methods ensure that naloxone can be administered quickly and efficiently, offering a vital second chance in life-threatening situations. Conclusion Faith-based addiction recovery programs offer a sanctuary for those seeking not just to quit substances, but to reawaken the spirit. They bridge the gap between sobriety and sanctity, providing a framework where healing is holistic, community-driven, and purpose-filled. In the often turbulent journey of addiction recovery, faith is not merely a companion—it is an anchor. TIME BUSINESS NEWS
